Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Suzanne J Baron , Robert P Giugliano Added: 3 years ago
Coronary artery disease remains the leading cause of death in the US and worldwide. Although the incidence of death due to coronary artery disease has declined over the last several years, the prevalence of coronary artery disease remains high, with the American Heart Association (AHA) estimating that over 81 million Americans suffer from cardiovascular disease and 2,200 people dying every day of… View more

Anticoagulation
Author(s): Franz-Josef Neumann Added: 3 years ago
Acute coronary syndromes (ACS) have been associated with the occurrence of cardiovascular (CV) events. Moderate- to high-risk ACS are generally managed by an early invasive approach, where coronary angiography is followed by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). However, ACS and the use of PCI or CABG are associated with a high risk of thrombotic… View more

Anticoagulation

MI/ACS
Author(s): Diego Penela , Maríbel Diaz-Ricart , Magda Heras Added: 3 years ago
The usual underlying mechanism of acute coronary syndromes (ACSs) is a thrombotic event caused by the rupture or erosion of an atherosclerotic plaque. In this scenario, platelets and thrombin are key players. Thus, understanding the physiopathology of platelet activation is of paramount importance in the treatment of acute coronary ischaemia. There is ample evidence showing that adequate… View more

Anticoagulation

MI/ACS
Author(s): Patrick Wong , Umair Shafique Added: 3 years ago
Cardiovascular (CV) events are a major cause of mortality worldwide1 that are often precipitated by acute coronary syndromes (ACS). ACS result from the acute obstruction of coronary arteries and are defined as either unstable angina (UA) or myocardial infarction (MI), with or without ST-segment-elevation (STEMI and NSTEMI, respectively). Patients with moderate- to high-risk ACS are managed by an… View more

Anticoagulation

MI/ACS
Author(s): Sasha Koul , David Erlinge Added: 3 years ago
Acute coronary syndromes (ACS) are a major reason for death and morbidity in the industrialised world. One of the most successful treatments for ACS has been strategies to target the platelets and inhibit their function. Mechanisms of Platelet Activation Thrombus formation in the arteries is dependent on platelets and their ability to attach to the injured wall despite the rapid arterial blood… View more

Anticoagulation

MI/ACS
Author(s): Kerry Layne , Albert Ferro Added: 3 years ago
Acute coronary syndrome (ACS) is a term used to encompass unstable angina (UA) and myocardial infarction (MI) with or without electrocardiographic (ECG) evidence of ST-segment elevation. Antiplatelet therapy has formed the backbone of ACS management for decades and the drug class continues to evolve as novel agents with increasingly efficacious antiplatelet actions are identified. The main risk… View more

Anticoagulation
Author(s): Renata Cífková Added: 3 years ago
Hypertension is the most prevalent cardiovascular disease affecting 20–50 % of the adult population.1 Elevated blood pressure has been identified as a risk factor for coronary heart disease (CHD), heart failure, stroke, peripheral arterial disease, renal failure and atrial fibrillation both in men and women in a large number of epidemiological studies.2–4 So far, the largest meta-analysis of… View more

Anticoagulation

Prevention & Chronic Conditions
Author(s): Laurent Bonello Added: 3 years ago
Clopidogrel is a key antiplatelet agent that inhibits the second step of platelet aggregation through blockade of the P2Y12-adenosine diphosphate (ADP) receptor.1 Its use has enabled percutaneous coronary intervention (PCI) to expand by dramatically reducing thrombotic complications in acute coronary syndromes (ACSs).2,3 Since the first report by Jaremo et al. of a large inter-individual… View more

Anticoagulation

MI/ACS
Prioritising Risk in CAD: A Patient-First Discussion on Antiplatelet Therapy
Author(s): Marco Valgimigli , Diana Gorog , Eliano Navarese , et al Added: 3 months ago
This on-demand version of the live roundtable, chaired by Prof Marco Valgimigli (Cardiocentro Ticino Institute, Lugano, CH), demonstrates how to prioritise bleeding and ischaemic risks in coronary arterial disease (CAD) management. Key opinion leaders Prof Diana Gorog (University of Hertfordshire, UK), Prof Felicita Andreotti (Gemelli University Hospital, Rome, IT) and Prof Eliano Navarese … View more

Anticoagulation
Prioritising Risk in CAD: A Patient-First Discussion on Antiplatelet Therapy
Author(s): Felicita Andreotti , Diana Gorog , Marco Valgimigli , et al Start date: Dec 14, 2023

Anticoagulation